Cargando…

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1

INTRODUCTION: The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Mease, Philip J., Soriano, Enrique R., Kishimoto, Mitsumasa, Salvarani, Carlo, Saffore, Christopher D., Zueger, Patrick, McDearmon-Blondell, Erin, Kato, Koji, Gladman, Dafna D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572257/
https://www.ncbi.nlm.nih.gov/pubmed/34636026
http://dx.doi.org/10.1007/s40744-021-00379-9
_version_ 1784595182682898432
author Strand, Vibeke
Mease, Philip J.
Soriano, Enrique R.
Kishimoto, Mitsumasa
Salvarani, Carlo
Saffore, Christopher D.
Zueger, Patrick
McDearmon-Blondell, Erin
Kato, Koji
Gladman, Dafna D.
author_facet Strand, Vibeke
Mease, Philip J.
Soriano, Enrique R.
Kishimoto, Mitsumasa
Salvarani, Carlo
Saffore, Christopher D.
Zueger, Patrick
McDearmon-Blondell, Erin
Kato, Koji
Gladman, Dafna D.
author_sort Strand, Vibeke
collection PubMed
description INTRODUCTION: The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1. METHODS: In this placebo- and active comparator, phase 3 randomized, controlled trial, patients received daily upadacitinib 15 or 30 mg, placebo, or adalimumab 40 mg every other week through 56 weeks. At week 24, placebo-assigned patients were rerandomized to upadacitinib 15 or 30 mg. PROs included Patient Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Short Form 36 Health Survey (SF-36), EQ-5D-5L index score, Bath Ankylosing Spondylitis Disease Activity Index, morning stiffness, Self-Assessment of Psoriasis Symptoms, and Work Productivity and Activity Impairment. Mean changes from baseline in PROs, improvements ≥ minimum clinically important differences (MCID), scores ≥ normative values, and sustained clinically meaningful responses were compared between treatment groups. RESULTS: At weeks 12 and 24, upadacitinib treatment resulted in improvements from baseline versus placebo across all PROs as well as improvements versus adalimumab in HAQ-DI and SF-36 Physical Component Summary score (nominal p < 0.05). Improvements in PtGA, pain, and HAQ-DI were reported as early as week 2. At week 12, significantly (nominal p < 0.05) more upadacitinib- versus placebo-treated patients reported improvements ≥ MCID across all PROs including seven SF-36 domains. The proportions of upadacitinib-treated patients reporting clinically meaningful improvements at week 12 were similar to or greater than with adalimumab and sustained through week 56. Significantly (nominal p < 0.05) more upadacitinib-treated (both doses) patients reported scores ≥ normative values at week 12 versus placebo, and scores were generally similar to or greater than adalimumab. CONCLUSIONS: Upadacitinib treatment provides rapid, sustained, and clinically meaningful improvements in PROs in non-bDMARD-IR patients with PsA. SELECT-PsA 1 ClinicalTrials.gov number, NCT03104400. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00379-9.
format Online
Article
Text
id pubmed-8572257
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-85722572021-11-15 Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1 Strand, Vibeke Mease, Philip J. Soriano, Enrique R. Kishimoto, Mitsumasa Salvarani, Carlo Saffore, Christopher D. Zueger, Patrick McDearmon-Blondell, Erin Kato, Koji Gladman, Dafna D. Rheumatol Ther Original Research INTRODUCTION: The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1. METHODS: In this placebo- and active comparator, phase 3 randomized, controlled trial, patients received daily upadacitinib 15 or 30 mg, placebo, or adalimumab 40 mg every other week through 56 weeks. At week 24, placebo-assigned patients were rerandomized to upadacitinib 15 or 30 mg. PROs included Patient Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Short Form 36 Health Survey (SF-36), EQ-5D-5L index score, Bath Ankylosing Spondylitis Disease Activity Index, morning stiffness, Self-Assessment of Psoriasis Symptoms, and Work Productivity and Activity Impairment. Mean changes from baseline in PROs, improvements ≥ minimum clinically important differences (MCID), scores ≥ normative values, and sustained clinically meaningful responses were compared between treatment groups. RESULTS: At weeks 12 and 24, upadacitinib treatment resulted in improvements from baseline versus placebo across all PROs as well as improvements versus adalimumab in HAQ-DI and SF-36 Physical Component Summary score (nominal p < 0.05). Improvements in PtGA, pain, and HAQ-DI were reported as early as week 2. At week 12, significantly (nominal p < 0.05) more upadacitinib- versus placebo-treated patients reported improvements ≥ MCID across all PROs including seven SF-36 domains. The proportions of upadacitinib-treated patients reporting clinically meaningful improvements at week 12 were similar to or greater than with adalimumab and sustained through week 56. Significantly (nominal p < 0.05) more upadacitinib-treated (both doses) patients reported scores ≥ normative values at week 12 versus placebo, and scores were generally similar to or greater than adalimumab. CONCLUSIONS: Upadacitinib treatment provides rapid, sustained, and clinically meaningful improvements in PROs in non-bDMARD-IR patients with PsA. SELECT-PsA 1 ClinicalTrials.gov number, NCT03104400. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00379-9. Springer Healthcare 2021-10-12 /pmc/articles/PMC8572257/ /pubmed/34636026 http://dx.doi.org/10.1007/s40744-021-00379-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Strand, Vibeke
Mease, Philip J.
Soriano, Enrique R.
Kishimoto, Mitsumasa
Salvarani, Carlo
Saffore, Christopher D.
Zueger, Patrick
McDearmon-Blondell, Erin
Kato, Koji
Gladman, Dafna D.
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
title Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
title_full Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
title_fullStr Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
title_full_unstemmed Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
title_short Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
title_sort improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from select-psa 1
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572257/
https://www.ncbi.nlm.nih.gov/pubmed/34636026
http://dx.doi.org/10.1007/s40744-021-00379-9
work_keys_str_mv AT strandvibeke improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT measephilipj improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT sorianoenriquer improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT kishimotomitsumasa improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT salvaranicarlo improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT safforechristopherd improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT zuegerpatrick improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT mcdearmonblondellerin improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT katokoji improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1
AT gladmandafnad improvementinpatientreportedoutcomesinpatientswithpsoriaticarthritistreatedwithupadacitinibversusplacebooradalimumabresultsfromselectpsa1